During the trials of its Covid vaccines, pharmaceutical giant Pfizer found that sudden deaths doubled after people had been injected with the mRNA shots.
The disturbing findings were revealed in a new analysis of Pfizer’s trial data.
Researchers found that sudden deaths were twice as high in the vaccine group of the original Pfizer clinical trial when compared those who received a placebo.
The researchers behind the new analysis are now raising the alarm about the safety of the novel mRNA drug.
Pfizer hasn’t made the data public, however, and has been battling in court to keep it sealed.
Researchers at the Health Advisory and Recovery Team (HART) found four more sudden deaths in the vaccine group than in the placebo group.
All of the sudden deaths occurred after the first 60 days of being injected.
Many assurances of vaccine safety assume that any damage will be seen within 28 days of vaccination, meaning signals after 60 days would be missed.
In total, there were 12 sudden deaths with no underlying cause: eight in the vaccine group and four in the placebo group.
Three occurred in each group during the first 60 days; subsequently, five occurred in the vaccine group but just one in the placebo group.
Even more concerning, the researchers warn, is that these four additional sudden deaths in the vaccine group account for the whole difference in the total number of deaths between the two groups: 20 in the vaccine group versus 16 in the placebo group.
By contrast, the six reported Covid deaths in the placebo group did not result in an excess of non-sudden deaths in the placebo group, as there were 12 non-sudden deaths in each group.
This suggests that while the vaccine did not prevent non-sudden deaths from causes such as Covid, it did cause sudden deaths.
However, while these figures from the trial are clearly a red flag that warrants urgent further investigation, the relatively small numbers involved mean the results are not statistically significant.
Statistically speaking, we can’t be more than 95% confident they did not occur by chance.
This is despite the trial involving 44,000 people.
If this rate of death occurred across the whole population it would equate to a vaccine mortality rate of around one per 5,000 people.
Such a signal must not be ignored, even if it falls below the significance threshold in this trial.
What it signals is a need for further investigation to confirm or rule out the risk.
The researchers note that the six Covid deaths in the placebo group amount to 38% of the 16 total deaths in that group.
The number is an extraordinarily high proportion that calls into question how the Covid deaths were identified.
The HART researchers also found evidence of potential bias in what was supposed to be a blinded trial.
The average length of time taken to report deaths in the vaccine group was two to three times longer than in the placebo group.
Tellingly, perhaps, the longest delays in the reporting of vaccine-group deaths occurred ahead of the critical interim report on which the vaccine’s emergency approval was based.
In that period, vaccine-group deaths took an incredible 18 days on average to report, while placebo-group deaths in the same period took just five days.
Mysteriously, vaccine-group death reporting then spent up to seven days on average, once the key interim data deadline had passed.
The HART team also drew attention to dubious classification decisions.
One example was a 65-year-old man from Texas whose death 11 days after receiving a Covid vaccine was categorized as unvaccinated.
He was marked as unvaxxed because, after unblinding, he had received the Moderna vaccine.
Since many of these apparent biases favor the vaccine, any estimate of harm should be understood as a lower bound.
Sudden deaths being twice as high in the vaccine group than the placebo group of a clinical trial should have rung alarm bells among regulators right from the start.
The fact that it didn’t only adds to the wider scandal around these experimental injections.